Safety Alerts & Recalls

What does this mean?

If you are taking Erivedge (vismodegib) and you are a woman of childbearing potential or a man you should have been informed of the risk of birth defects linked to this medicine. You should also have been advised of measures to prevent pregnancy and that you should not give blood. Pharmacists have now been given a more important role in ensuring these messages are passed on effectively and so they may now speak to you to confirm this when your prescriptions are dispensed. If you have any questions about the contents of this alert or your treatment with Erivedge you should ask your doctor or pharmacist for advice.

Healthcare Professionals Advised Not to Use Erivedge in Women of Childbearing Potential

Roche Products has written to healthcare professionals to remind them that Erivedge (vismodegib) can cause birth defects and should not be used in pregnancy, and also to inform them of an increased role for pharmacists when the drug is prescribed. If women of childbearing potential or men (because Erivedge is contained in semen) are prescribed it they should take measures to prevent pregnancy. Patients must not donate blood while taking Erivedge and for 24 months after the final dose. Before dispensing Erivedge, pharmacists must now prove that all patients have been given suitable advice about the risks of taking it and the measures to minimise this risk. Erivedge is used to treat skin cancer

For more information, please visit: more information here

Source: MHRA
Publication Date: 2015-02-19
Last Updated: 2015-02-19
Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download our free mobile app for daily design news on the go. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones